Skip to Main Content
TABLE 3

Insulin sensitivity, β-cell function, and body weight in the TRIPOD and PIPOD studies

VariableBaseline TRIPOD (period 1)Baseline PIPOD (period 2)End PIPOD (period 3)P value (2 vs. 1)*P value (3 vs. 2)*
TRIPOD troglitazone group (n = 27)      
    Si (min · μU−1 · ml−1 · 10−42.38 ± 1.52 2.81 ± 2.09 2.50 ± 2.56 0.23 0.57 
    AIRg (μU · ml−1 · min−1453 ± 283 479 ± 309 392 ± 207 0.60 0.13 
    DI 913 ± 518 1,095 ± 607 878 ± 598 0.24 0.12 
    Weight (kg) 69.1 ± 10.9 73.0 ± 11.0 75.0 ± 11.2 <0.0001 0.006 
TRIPOD placebo group (n = 32)      
    Si (min · μU−1 · ml−1 · 10−42.79 ± 2.32 2.24 ± 1.24 2.16 ± 1.34 0.16 0.72 
    AIRg (μU · ml−1 · min−1593 ± 554 382 ± 285 484 ± 357 0.03 0.13 
    DI 1125 ± 687 754 ± 542 953 ± 678 0.003 0.14 
    Weight (kg) 68.3 ± 8.8 69.4 ± 8.0 72.3 ± 9.6 0.15 0.0004 
VariableBaseline TRIPOD (period 1)Baseline PIPOD (period 2)End PIPOD (period 3)P value (2 vs. 1)*P value (3 vs. 2)*
TRIPOD troglitazone group (n = 27)      
    Si (min · μU−1 · ml−1 · 10−42.38 ± 1.52 2.81 ± 2.09 2.50 ± 2.56 0.23 0.57 
    AIRg (μU · ml−1 · min−1453 ± 283 479 ± 309 392 ± 207 0.60 0.13 
    DI 913 ± 518 1,095 ± 607 878 ± 598 0.24 0.12 
    Weight (kg) 69.1 ± 10.9 73.0 ± 11.0 75.0 ± 11.2 <0.0001 0.006 
TRIPOD placebo group (n = 32)      
    Si (min · μU−1 · ml−1 · 10−42.79 ± 2.32 2.24 ± 1.24 2.16 ± 1.34 0.16 0.72 
    AIRg (μU · ml−1 · min−1593 ± 554 382 ± 285 484 ± 357 0.03 0.13 
    DI 1125 ± 687 754 ± 542 953 ± 678 0.003 0.14 
    Weight (kg) 68.3 ± 8.8 69.4 ± 8.0 72.3 ± 9.6 0.15 0.0004 

Data are means ± SD from 59 women who had IVGTTs performed at enrollment into to TRIPOD (period 1), at enrollment into PIPOD (period 2, equivalent to end of postdrug washout period for TRIPOD), and end of postdrug washout period in PIPOD (period 3), so that all results were obtained remote from any acute drug effects.

*

By paired t test.

Close Modal

or Create an Account

Close Modal
Close Modal